Table 1 Patient clinicopathologic characteristics in the NCR and TEAM cohorts
Characteristics | n (%) | |
|---|---|---|
NCR Cohort (n = 1264) | TEAM Cohort (n = 978) | |
Age at surgery, years | ||
Mean ± SD | 78 ± 5 | 67 ± 8 |
<50 | 0 | 4 (0.4) |
50–59 | 0 | 201 (20.6) |
60–69 | 0 | 419 (42.8) |
70–74 | 504 (39.9) | 175 (17.9) |
75–79 | 273 (21.6) | 125 (12.8) |
≥80 | 487 (38.5) | 54 (5.5) |
Tumor size, mm | ||
≤20 | 638 (50.5) | 528 (54.0) |
>20 | 626 (49.5) | 449 (45.9) |
Unknown | 0 | 1 (0.1) |
Tumor grade | ||
Well | 272 (21.5) | 38 (3.9) |
Moderate | 769 (60.8) | 544 (55.6) |
Poor | 223 (17.6) | 356 (36.4) |
Unknown | 0 | 40 (4.1) |
PR status | ||
PR– | 240 (19.0) | 163 (16.7) |
PR+ | 971 (76.8) | 677 (69.2) |
Unknown | 53 (4.2) | 138 (14.1) |
Surgery type | ||
Mastectomy | 703 (55.6) | 401 (41.0) |
Lumpectomy | 561 (44.4) | 577 (59.0) |
Adjuvant endocrine therapy | ||
Tamoxifen | 480 (38.0) | |
Aromatase inhibitor | 190 (15.0) | 503 (51.4) |
Sequential | 415 (32.8) | 475 (48.6) |
Unknown | 179 (14.2) | 0 |
Disease recurrence | ||
Locoregional | 26 (2.1) | 26 (2.7) |
Distant | 83 (6.6) | 93 (9.5) |
